LAUSR

MMR: mumps, measles, and rubella PPD: purified protein derivative INTRODUCTION Multiple recalcitrant warts represent a continuing therapeutic challenge for both patients and physicians. Recently, intralesional immunotherapy by different antigens has been associated with promising efficacy and safety in the treatment of different types of warts, including recalcitrant ones. The therapeutic response to different types of intralesional antigens varies considerably between different studies. Many factors may explain this variability, including the differences in the type of the injected antigen, in the sensitivity and quantity of the injected antigen, in the studied population, and in the induction power of the T helper cell type 1 cytokine response. It has been assumed that the absent or partial response to intralesional antigen immunotherapy may represent a failure of specific antigen rather than a failure of modality. Therefore, we propose that shifting from one intralesional antigen to another is a potential therapeutic option for individuals who have failed to respond. Herein, we present 2 cases of multiple recalcitrant warts that showed complete clearance with intralesional Candida antigen after failure of 5 sessions ofmumps, measles, and rubella (MMR) vaccine and purified protein derivative (PPD).